408 related articles for article (PubMed ID: 30518618)
1. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
[TBL] [Abstract][Full Text] [Related]
2. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
3. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
Abrahami D; Yin H; Yu OHY; Pollak MN; Azoulay L
Epidemiology; 2018 Mar; 29(2):246-253. PubMed ID: 29283894
[TBL] [Abstract][Full Text] [Related]
5. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study.
Pradhan R; Lu S; Yin H; Yu OHY; Ernst P; Suissa S; Azoulay L
BMJ; 2022 Nov; 379():e071380. PubMed ID: 36318979
[TBL] [Abstract][Full Text] [Related]
6. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
7. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
Faillie JL; Yu OH; Yin H; Hillaire-Buys D; Barkun A; Azoulay L
JAMA Intern Med; 2016 Oct; 176(10):1474-1481. PubMed ID: 27478902
[TBL] [Abstract][Full Text] [Related]
8. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
[TBL] [Abstract][Full Text] [Related]
9. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.
Hicks BM; Yin H; Yu OH; Pollak MN; Platt RW; Azoulay L
BMJ; 2016 Oct; 355():i5340. PubMed ID: 27797785
[TBL] [Abstract][Full Text] [Related]
11. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study.
Bea S; Son H; Bae JH; Cho SW; Shin JY; Cho YM
Diabetes Obes Metab; 2024 Jan; 26(1):108-117. PubMed ID: 37735822
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Rouette J; Yin H; Yu OHY; Bouganim N; Platt RW; Azoulay L
Diabet Med; 2020 May; 37(5):868-875. PubMed ID: 32124472
[TBL] [Abstract][Full Text] [Related]
14. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
[TBL] [Abstract][Full Text] [Related]
15. Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study.
Yang CT; Yang CY; Ou HT; Kuo S
Cardiovasc Diabetol; 2020 Jun; 19(1):83. PubMed ID: 32534570
[TBL] [Abstract][Full Text] [Related]
16. Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes.
Lu S; Yin H; Yu OHY; Azoulay L
Epidemiology; 2022 Jul; 33(4):563-571. PubMed ID: 35394977
[TBL] [Abstract][Full Text] [Related]
17. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
Faillie JL; Azoulay L; Patenaude V; Hillaire-Buys D; Suissa S
BMJ; 2014 Apr; 348():g2780. PubMed ID: 24764569
[TBL] [Abstract][Full Text] [Related]
18. Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes.
O'Brien MJ; Karam SL; Wallia A; Kang RH; Cooper AJ; Lancki N; Moran MR; Liss DT; Prospect TA; Ackermann RT
JAMA Netw Open; 2018 Dec; 1(8):e186125. PubMed ID: 30646315
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
Gokhale M; Buse JB; Gray CL; Pate V; Marquis MA; Stürmer T
Diabetes Obes Metab; 2014 Dec; 16(12):1247-56. PubMed ID: 25109825
[TBL] [Abstract][Full Text] [Related]
20. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
Simms-Williams N; Treves N; Yin H; Lu S; Yu O; Pradhan R; Renoux C; Suissa S; Azoulay L
BMJ; 2024 Apr; 385():e078242. PubMed ID: 38663919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
